MDGA2 is a novel tumour suppressor cooperating with DMAP1 in gastric cancer and is associated with disease outcome

BACKGROUND: Using the promoter methylation assay, we have shown that MDGA2 (MAM domain containing glycosylphosphatidylinositol anchor 2) is preferentially methylated in gastric cancer. We analysed its biological effects and prognostic significance in gastric cancer. METHODS: MDGA2 methylation status...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Kunning, Liang, Qiaoyi, Li, Xiaoxing, Tsoi, Ho, Zhang, Jingwan, Wang, Hua, Go, Minnie Y Y, Chiu, Philip W Y, Ng, Enders K W, Sung, Joseph J Y, Yu, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2016
Materias:
Stomach
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5036270/
https://www.ncbi.nlm.nih.gov/pubmed/26206665
http://dx.doi.org/10.1136/gutjnl-2015-309276

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5036270/
https://www.ncbi.nlm.nih.gov/pubmed/26206665
http://dx.doi.org/10.1136/gutjnl-2015-309276

Ejemplares similares